Search the Newsreel

CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has lowered its price target for CytomX Therapeutics (NASDAQ:CTMX) from $12.00 to $11.00, while maintaining an "overweight" rating. This new target suggests a potential upside of 227.19% from the stock's previous close. The adjustment follows CytomX Therapeutics' recent quarterly report, …

CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in CytomX Therapeutics by 49.7% in the first quarter, now owning 1.93 million shares worth $9.07 million. Despite missing analyst expectations for Q1 earnings and revenue, the company maintains a "Buy" rating from analysts with a …

CytomX Therapeutics (CTMX) Stock Faces Revenue Collapse As Pipeline Hopes Carry The Story

CytomX Therapeutics (CTMX) saw its stock edge up slightly despite a significant revenue collapse and widened net loss in Q2 2026. The company's future prospects heavily rely on the success of its drug pipeline, particularly the PROBODY platform and Varseta M, as legacy collaborations …

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Buy" by Brokerages

Analysts have issued a "Buy" consensus rating for CytomX Therapeutics (NASDAQ:CTMX), with an average 12-month price target of $12.10, significantly higher than its current share price of $3.46. Despite this positive outlook, the company reported a wider-than-expected quarterly loss of $0.09 per share and …

CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results

CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlight

CytomX Therapeutics is advancing its lead asset, Varetta M, towards a registrational study in late-line colorectal cancer, with promising preliminary progression-free survival data. Despite a significant revenue decline and increased operating expenses, the company maintains a solid financial runway, bolstered by an expanded collaboration …

CytomX Therapeutics, Inc. Stock 12‑Month Price Target Cut to $12.38, Implies 267% Upside

CytomX Therapeutics, Inc. (CTMX) has seen its average 12-month price target cut slightly from $12.50 to $12.38 by 8 analysts. This updated target suggests a significant potential upside of approximately 267% from its August 6th closing price. The consensus rating among these analysts remains …

State Street Corporation (CTMX) reports 5.4% beneficial stake in CytomX Therapeutics

State Street Corporation has reported a beneficial ownership of 5.4% in CytomX Therapeutics, Inc., holding 11,747,236 shares of common stock. The filing indicates shared voting power over 11,471,693 shares and shared dispositive power over all 11,747,236 shares, with no sole voting or dispositive power. …

CytomX Therapeutics Inc earnings missed, revenue fell short of estimates

CytomX Therapeutics Inc (NASDAQ: CTMX) reported second-quarter earnings per share of $-0.090, missing analyst estimates of $-0.080, and revenue of $1.41M, significantly below the consensus estimate of $11.33M. The company's stock is down 15.200% in the last three months but up 60.710% in the …

CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises

CytomX (NASDAQ: CTMX) reported a significant decline in Q2 2026 revenue to $1.4 million, down from $18.7 million year-over-year, and a widened net loss of $20.7 million primarily due to decreased collaboration revenue and increased R&D spending. Despite the financial setbacks, the company maintained …

Earnings call transcript: CytomX misses Q2 2026 estimates as cash runway extends

CytomX Therapeutics reported a wider-than-expected Q2 2026 loss and a significant revenue drop, but its stock remained stable due to a strong cash reserve, a new Regeneron milestone payment, and promising early data for its lead cancer drug, Varseta-M. The company is strategically shifting …

CytomX Therapeutics posts Q2 2026 results — $1.4M revenue, $25.2M operating expense, $330.3M cash

CytomX Therapeutics reported Q2 2026 results with $1.4 million in revenue and $25.2 million in operating expenses, resulting in a $23.8 million operating loss. The company holds $330.3 million in cash, equivalents, and investments, projecting a financial runway until at least the second half …

CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

CytomX Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The report is available through Refinitiv, and the full article can be accessed by TradingView users. This news was originally reported by Reuters.

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CytomX Therapeutics reported Q2 2026 revenue of $1.4 million and a net loss of $20.7 million, ending the quarter with $330.3 million in cash, projecting a runway to at least 2H 2028. The company completed enrollment for its Varseta-M Phase 1 CRC monotherapy trial …

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) reported a Q2 loss of $0.09 per share, exceeding the Zacks Consensus Estimate of a $0.11 loss, marking an 18.18% surprise. However, the company missed revenue estimates significantly, posting $1.42 million against an expected $7.18 million. Shares have declined 21.4% year-to-date, …

CytomX Therapeutics, Inc. (CTMX) Chief Legal Officer files Form 3 insider report

CytomX Therapeutics, Inc. announced that its Chief Legal Officer, Alejandra Carvajal, has become a "reporting insider" by filing a Form 3. This initial insider report indicates no transactions in CytomX securities, and it includes a Power of Attorney for future Section 16-related actions. The …

CytomX Therapeutics Chief Legal Officer Alejandra Carvajal files initial beneficial ownership statement

CytomX Therapeutics' Chief Legal Officer, Alejandra Carvajal, has filed an initial beneficial ownership statement (Form 3). This news brief was generated by Public Technologies (PUBT) using AI, based on original content filed with the U.S. Securities and Exchange Commission (SEC) via EDGAR on August …

CytomX Therapeutics, Inc. (CTMX) awards 450,000 options and 100,000 RSUs to CLO

CytomX Therapeutics, Inc. (CTMX) granted its Chief Legal Officer, Alejandra Carvajal, 450,000 stock options and 100,000 Restricted Stock Units (RSUs) on August 3, 2026. The stock options have an exercise price of $3.17 per share and vest over four years, while the RSUs vest …

Press Release: CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CytomX Therapeutics has appointed Alejandra Carvajal as its new Chief Legal Officer. Carvajal brings over 20 years of legal experience in the biopharmaceutical industry, with a strong background in corporate law, M&A, intellectual property, and compliance. This appointment is expected to bolster CytomX's leadership …

Bank of America (NYSE: BAC) discloses 7.0% ownership stake in CytomX (CTMX)

Bank of America Corporation has filed a Schedule 13G, revealing a 7.0% beneficial ownership stake in CytomX Therapeutics, Inc. This stake, amounting to 15,134,689 shares, is primarily held through its wholly-owned subsidiaries, including BofA Securities, Inc. and Merrill Lynch entities. While Bank of America …

InvestingPro’s Fair Value predicted 46% drop in CytomX stock By Investing.com

InvestingPro's Fair Value analysis accurately predicted a 46% drop in CytomX Therapeutics (NASDAQ:CTMX) stock. The analysis, conducted in January 2026 when the stock was trading at $5.73, identified significant overvaluation. Six months later, shares had fallen to $3.10, validating InvestingPro's methodology which aggregates various …

BlackRock, Inc. Adds to CytomX Therapeutics Inc (CTMX) Stake -- Shares Look 1007% Overvalued on GF Value

BlackRock, Inc. increased its stake in CytomX Therapeutics Inc (CTMX) by 216.58% on June 30, 2026, purchasing 11,323,172 additional shares at $3.75 each, despite the stock being deemed significantly overvalued by GuruFocus. As of August 1, 2026, CTMX shares had dropped to $3.10, resulting …

CytomX Therapeutics (CTMX) awards 118,000 stock options to board director

CytomX Therapeutics awarded 118,000 stock options to board director Charles S. Fuchs. The options have an exercise price of $3.24 per share, expire on July 23, 2036, and vest over three years starting from July 24, 2026, contingent on his continued service. This transaction …

Form 4 CytomX Therapeutics Inc For: 31 July By Investing.com

This article reports on a Form 4 filing for CytomX Therapeutics Inc. dated July 31st. It indicates that the filing is available through Investing.com, a financial markets platform. The content is primarily a placeholder for the actual Form 4 document.

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026, after the close of U.S. markets. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT following …

CytomX's second-quarter results call is set for Aug. 6 at 5 p.m. ET

CytomX Therapeutics (Nasdaq: CTMX) is scheduled to report its second-quarter 2026 financial results on August 6, 2026, after market close, followed by a conference call and webcast at 5:00 p.m. ET. The company, which is a clinical-stage, oncology-focused biopharmaceutical firm developing PROBODY therapeutics, has …

CytomX Therapeutics (CTMX) Projected to Announce Quarterly Earnings on Thursday

Operating cash flow per share of CytomX Therapeutics, Inc. – LSX:A14158

This article provides financial information for CytomX Therapeutics, Inc. (LSX:A14158), specifically focusing on its operating cash flow per share. The content presents a table showing the value, change, and percentage change over a given period, stating that this information was "Made by humans."

CytomX Therapeutics Inc (CTMX) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of CytomX Therapeutics Inc (CTMX), reporting its current financial score as 7.59, which ranks it 106 out of 385 in the Biotechnology & Medical Research industry. While its financial status is stable and operating efficiency is high, the …

Eversept Partners LP Has $14.99 Million Stock Holdings in CytomX Therapeutics, Inc. $CTMX

CytomX appoints Charles Fuchs to board of directors By Investing.com

CytomX Therapeutics has appointed Charles Fuchs, M.D., M.P.H., to its board of directors. Fuchs brings extensive experience from both the pharmaceutical industry, where he held senior roles at Genentech and Roche, and academia, having served as Director of the Yale Cancer Center. CytomX is …

Charles Fuchs appointed to CytomX Board as Class II director

CytomX Therapeutics (CTMX) has appointed Charles Fuchs as a Class II director, effective July 24, 2026, with his term extending through the 2029 annual meeting. As part of his compensation, he will receive standard non-employee director compensation and an option for 118,000 shares which …

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

CytomX Therapeutics has appointed Charles Fuchs, M.D., M.P.H., a board-certified medical oncologist with over three decades of oncology leadership experience, to its Board of Directors. Dr. Fuchs' extensive background in oncology product development, including his expertise in gastrointestinal oncology, is expected to be invaluable …